MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Veracyte Inc

Cerrado

SectorSanidad

28.45 -5.42

Resumen

Variación precio

24h

Actual

Mínimo

27.89

Máximo

30.11

Métricas clave

By Trading Economics

Ingresos

-10M

5.1M

Ventas

2.8M

119M

P/B

Media del Sector

95.645

63.778

BPA

0.36

Margen de beneficios

4.31

Empleados

824

EBITDA

-13M

9.7M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+48.39% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-1.2B

2.3B

Apertura anterior

33.87

Cierre anterior

28.45

Noticias sobre sentimiento de mercado

By Acuity

12%

88%

14 / 386 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

Veracyte Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

3 abr 2025, 23:04 UTC

Principales Noticias

JPMorgan Raises Risk of U.S., Global Recession to 60%

3 abr 2025, 22:40 UTC

Principales Movimientos del Mercado

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

3 abr 2025, 22:18 UTC

Adquisiciones, fusiones, absorciones

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

3 abr 2025, 18:51 UTC

Adquisiciones, fusiones, absorciones

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

3 abr 2025, 23:43 UTC

Charlas de Mercado

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

3 abr 2025, 23:41 UTC

Charlas de Mercado

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

3 abr 2025, 22:22 UTC

Adquisiciones, fusiones, absorciones

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 abr 2025, 22:21 UTC

Adquisiciones, fusiones, absorciones

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 abr 2025, 21:43 UTC

Principales Noticias
Ganancias

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

3 abr 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

3 abr 2025, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

3 abr 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

3 abr 2025, 20:43 UTC

Charlas de Mercado

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

3 abr 2025, 20:34 UTC

Principales Noticias

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

3 abr 2025, 20:23 UTC

Principales Noticias

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

3 abr 2025, 20:15 UTC

Adquisiciones, fusiones, absorciones

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3 abr 2025, 19:55 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

3 abr 2025, 19:55 UTC

Charlas de Mercado

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

3 abr 2025, 19:21 UTC

Charlas de Mercado

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

3 abr 2025, 19:15 UTC

Charlas de Mercado

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

3 abr 2025, 18:45 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

3 abr 2025, 18:45 UTC

Charlas de Mercado

Gold Drops In Tariff Fallout -- Market Talk

3 abr 2025, 18:39 UTC

Charlas de Mercado

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

3 abr 2025, 18:38 UTC

Principales Noticias

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

3 abr 2025, 18:30 UTC

Principales Noticias

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

3 abr 2025, 18:20 UTC

Charlas de Mercado

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

3 abr 2025, 18:18 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

3 abr 2025, 18:17 UTC

Charlas de Mercado

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

3 abr 2025, 18:04 UTC

Charlas de Mercado

US Sees More Job Openings in Construction, Transportation -- Market Talk

3 abr 2025, 17:55 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Veracyte Inc previsión

Precio Objetivo

By TipRanks

48.39% repunte

Estimación a 12 Meses

Media 44.71 USD  48.39%

Máximo 51 USD

Mínimo 29 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Veracyte Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

8 ratings

7

Comprar

0

Mantener

1

Vender

Puntuación técnica

By Trading Central

29.65 / 31.78Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

14 / 386 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Veracyte Inc

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.